RxDoctor Payments Data

Andrea Johnson

Psychiatric/Mental Health · Waverly, IANPI 1477142289

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 659 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,150in general payments, 2019–2025

Across 659 payments — averaging $12.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Alkermes, Inc.$963
  • Otsuka America Pharmaceutical, Inc.$884
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$789
  • Johnson & Johnson$739
  • Teva Pharmaceuticals USA, Inc.$624
  • plus $3K from 13 others

What the payments were for

  • Food & beverage$7,92197%
  • Education$2303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,150 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$28,809
Medicare patients
75
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate65$506,624
Invega SustennaPaliperidone Palmitate110$319,250
VraylarCariprazine Hcl103$143,726
Abilify MaintenaAripiprazole51$134,331
RexultiBrexpiprazole55$82,988
LybalviOlanzapine/Samidorphan Malate35$55,072
Risperdal ConstaRisperidone Microspheres40$49,288
CaplytaLumateperone Tosylate24$39,599
Loreev XrLorazepam62$27,388
QuviviqDaridorexant Hcl41$20,396
Paliperidone ErPaliperidone115$18,077
TrintellixVortioxetine Hydrobromide36$15,880
AuvelityDextromethorphan Hbr/Bupropion15$13,296
Clozapine51$4,894
Aripiprazole101$4,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,335$506,62465 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$739$368,538150 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$884$217,319106 claims
AbbVieVraylar$402$143,726103 claims
Alkermes, Inc.Lybalvi$963$55,07235 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$789$39,59924 claims
Almatica Pharma LLCLoreev Xr$80$27,38862 claims
Idorsia Pharmaceuticals US IncQuviviq$24$20,39641 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$178$15,88036 claims
Axsome Therapeutics, Inc.Auvelity$157$13,29615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Waverly

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →